Eloxx Pharmaceuticals, Inc. (ELOX) stock
ELOXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$10.41−1.33 (-11.33%)
Close on Nov 18, 2026Market cap $70.68MP/E –Yield –
Eloxx Pharmaceuticals operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Eloxx Pharmaceuticals's operating income for the twelve months ending Dec 31, 2023 was -$17.29M. For fiscal 2025 it was -$6.44M. The highest annual figure on record is -$2.47M in fiscal 2024.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$6.44M | – |
| FY2024 | Dec 31, 2024 | -$2.47M | – |
| FY2023 | Dec 31, 2023 | -$17.29M | – |
| FY2022 | Dec 31, 2022 | -$34.42M | – |
| FY2021 | Dec 31, 2021 | -$66.02M | – |
| FY2020 | Dec 31, 2020 | -$33.46M | – |
| FY2019 | Dec 31, 2019 | -$50.56M | – |
| FY2018 | Dec 31, 2018 | -$47.57M | – |
| FY2016 | Jun 30, 2016 | -$11.19M | – |
| FY2015 | Jun 30, 2015 | -$18.08M | – |
| FY2014 | Jun 30, 2014 | -$9.15M | – |
| FY2013 | Jun 30, 2013 | -$4.65M | – |
| FY2012 | Jun 30, 2012 | -$5.41M | – |
| FY2011 | Jun 30, 2011 | -$7.92M | – |
| FY2010 | Jun 30, 2010 | -$4.85M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026CQ2 2026 | Jun 30, 2026 | -$4.45M | – |
| Q1 FY2026CQ1 2026 | Mar 31, 2026 | -$3.80M | – |
| Q2 FY2025CQ2 2025 | Jun 30, 2025 | -$1.58M | – |
| Q1 FY2025CQ1 2025 | Mar 31, 2025 | -$1.22M | – |
| Q4 FY2023CQ4 2023 | Dec 31, 2023 | -$4.03M | – |
| Q3 FY2023CQ3 2023 | Sep 30, 2023 | -$3.64M | – |
| Q2 FY2023CQ2 2023 | Jun 30, 2023 | -$4.14M | – |
| Q1 FY2023CQ1 2023 | Mar 31, 2023 | -$5.48M | – |
| Q4 FY2022CQ4 2022 | Dec 31, 2022 | -$6.03M | – |
| Q3 FY2022CQ3 2022 | Sep 30, 2022 | -$7.14M | – |
| Q2 FY2022CQ2 2022 | Jun 30, 2022 | -$10.30M | – |
| Q1 FY2022CQ1 2022 | Mar 31, 2022 | -$10.95M | – |
| Q4 FY2021CQ4 2021 | Dec 31, 2021 | -$11.63M | – |
| Q3 FY2021CQ3 2021 | Sep 30, 2021 | -$10.25M | – |
| Q2 FY2021CQ2 2021 | Jun 30, 2021 | -$35.73M | – |
| Q1 FY2021CQ1 2021 | Mar 31, 2021 | -$8.41M | – |
| Q4 FY2020CQ4 2020 | Dec 31, 2020 | -$5.81M | – |
| Q3 FY2020CQ3 2020 | Sep 30, 2020 | -$6.30M | – |
| Q2 FY2020CQ2 2020 | Jun 30, 2020 | -$7.59M | – |
| Q1 FY2020CQ1 2020 | Mar 31, 2020 | -$13.77M | – |
| Q4 FY2019CQ4 2019 | Dec 31, 2019 | -$11.49M | – |
| Q3 FY2019CQ3 2019 | Sep 30, 2019 | -$12.78M | – |
| Q2 FY2019CQ2 2019 | Jun 30, 2019 | -$14.31M | – |
| Q1 FY2019CQ1 2019 | Mar 31, 2019 | -$11.98M | – |
| Q4 FY2018CQ4 2018 | Dec 31, 2018 | -$14.11M | – |
| Q3 FY2018CQ3 2018 | Sep 30, 2018 | -$11.36M | – |
| Q2 FY2018CQ2 2018 | Jun 30, 2018 | -$13.54M | – |
| Q1 FY2018CQ1 2018 | Mar 31, 2018 | -$8.55M | – |
| Q4 FY2016CQ2 2016 | Jun 30, 2016 | -$1.40M | – |
| Q3 FY2016CQ1 2016 | Mar 31, 2016 | -$4.89M | – |
| Q2 FY2016CQ4 2015 | Dec 31, 2015 | -$3.76M | – |
| Q1 FY2016CQ3 2015 | Sep 30, 2015 | -$1.15M | – |
| Q4 FY2015CQ2 2015 | Jun 30, 2015 | -$919.03K | – |
| Q3 FY2015CQ1 2015 | Mar 31, 2015 | -$1.22M | – |
| Q2 FY2015CQ4 2014 | Dec 31, 2014 | -$10.75M | – |
| Q1 FY2015CQ3 2014 | Sep 30, 2014 | -$5.19M | – |
| Q4 FY2014CQ2 2014 | Jun 30, 2014 | -$3.68M | – |
| Q3 FY2014CQ1 2014 | Mar 31, 2014 | -$2.13M | – |
See a number that looks wrong?